Predictive genomics: A cancer hallmark network framework for predicting
  tumor clinical phenotypes using genome sequencing data by Wang, Edwin et al.
 1 
Predictive genomics: A cancer hallmark network framework 
for predicting tumor clinical phenotypes using genome 
sequencing data 
 
 
Edwin Wang1,2,*, Naif Zaman1,3, Shauna Mcgee1,4, Jean-Sébastien Milanese1,5, Ali 
Masoudi-Nejad6 and Maureen O'Connor1 
 
1. National Research Council Canada, Montreal, QC H4P 2R2, Canada  
2. Center for Bioinformatics, McGill University, Montreal, QC H3G 0B1, Canada 
3. Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 
2B2, Canada 
4. Department of Experimental Medicine, McGill University, Montreal, QC H3A 1A3, 
Canada 
5. Department of Medicine, Laval University, Quebec, QC G1V 0A6, Canada 
6. Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry 
and Biophysics, University of Tehran, Tehran, Iran 
 
 
 
*Corresponding author: Edwin Wang (edwin.wang@cnrc-nrc.gc.ca) 
 
 
 2 
Abstract 
Tumor genome sequencing leads to documenting thousands of DNA mutations and other 
genomic alterations. At present, these data cannot be analyzed adequately to aid in the 
understanding tumorigenesis and its evolution. Moreover, we have little insight into how 
to use these data to predict clinical phenotypes and tumor progression to better design 
patient treatment. To meet these challenges, we discuss a cancer hallmark network 
framework for modeling genome sequencing data to predict cancer clonal evolution and 
associated clinical phenotypes. The framework includes: (1) cancer hallmarks that can be 
represented by a few molecular/signaling networks.  ‘Network operational signatures’ 
which represent gene regulatory logics/strengths enable to quantify state transitions and 
measures of hallmark traits. Thus, sets of genomic alterations which are associated with 
network operational signatures could be linked to the state/measure of hallmark traits. 
The network operational signature transforms genotypic data (i.e., genomic alterations) to 
regulatory phenotypic profiles (i.e., regulatory logics/strengths), to cellular phenotypic 
profiles (i.e., hallmark traits) which lead to clinical phenotypic profiles (i.e., a collection 
of hallmark traits). Furthermore, the framework considers regulatory logics of the 
hallmark networks under tumor evolutionary dynamics and therefore also includes: (2) a 
self-promoting positive feedback loop that is dominated by a genomic instability network 
and a cell survival/proliferation network is the main drivers of tumor clonal evolution. 
Surrounding tumor stroma and its host immune systems shape the evolutionary paths; (3) 
cell motility initiating metastasis is a byproduct of the above self-promoting loop activity 
during tumorigenesis; (4) an emerging hallmark network which triggers genome 
duplication dominates a feed-forward loop which in turn could act as a rate-limiting step 
for tumor formation; (5) mutations and other genomic alterations with specific patterns 
and tissue-specificity, which are driven by aging and other cancer-inducing agents.  
This framework represents the logics of complex cancer biology as a myriad of 
phenotypic complexities governed by a limited set of underlying organizing principles. It 
therefore adds to our understanding of tumor evolution and tumorigenesis, and moreover, 
potential usefulness of predicting tumors’ evolutionary paths and clinical phenotypes. 
Strategies of using this framework in conjunction with genome sequencing data in an 
attempt to predict personalized drug targets, drug resistance, and metastasis for a cancer 
patient, as well as cancer risks for a healthy individual are discussed. Accurate prediction 
of cancer clonal evolution and clinical phenotypes will have substantial impact on timely 
diagnosis, personalized management and prevention of cancer.  
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1 Introduction 
Tumor genome sequencing has generated information on thousands of mutations and 
other genomic alterations. To date, more than 10,000 tumor genomes have been 
sequenced and as sequencing costs drop, many more genomes will be determined in the 
near future. Recently, Illumina released a high-throughput genetic sequencing machine, 
the HiSeq X Ten that can sequence a whole human genome for $1,000. New technologies 
such as Quantum Sequencing platform and Oxford Nanopore systems hold promise for 
further reducing genome sequencing cost in the future. This trend suggests that genome 
sequencing could be used as a diagnostic tool in clinical practice. 
Tumor genome sequencing has cataloged many ‘driver-mutating genes’ and will continue 
to catalog more. However, the biological complexity of cancer combined with a vast 
amount of genome sequencing data presents a significant challenge on how to extract 
useful information and translate them into mechanistic understandings and predictions for 
cancer phenotypes [1], thus enabling management of cancer patient treatment in a more 
efficient manner. If one looks at a cancer cell genome, it is abundant with gene mutations, 
deletions and amplifications, chromosome gains and losses. Though seemingly random, 
there could in fact be patterns for mutations and chromosomal changes and by 
uncovering these patterns, we could in turn gain more insight into the mechanisms which 
drive cancer progression. By accessing the complete, precise genomic and clinical 
information from cancer patients, future advances will depend on exploiting the natural 
genetic complexity through uncovering key components of the cancer system.  The 
genetic complexity observed can be described in a mathematical manner and models 
computed as a result. Moreover, the key components of cancer could be experimentally 
perturbed to test their characteristics. Ultimately, we could predict evolutionary path of 
the tumor clones and their phenotypes associated with progression, metastases and drug 
resistance.       
In this review, we discuss a cancer hallmark network framework that can be used to 
model key components of cancer systems and then link mutant genotypes (i.e., mutations 
and other genomic alterations) to cellular and clinical genotypes. Using this framework, 
we illustrate strategies for prediction of cancer drug targets, probability of tumor 
recurrence, and cancer risks based on individual patient’s genome sequencing profile. 
Predictions derived from cancer hallmark network-based modeling could ultimately be 
used in diagnosis and optimized patient management and prevention of cancer.  
2 Cancer hallmarks and their networks  
Although the biology of cancer is extremely complex, key traits have been revealed 
during the past decade. The complexity of cancer can be reduced and represented by a 
few distinctive and complementary capabilities (‘cancer hallmarks’) that enable tumor 
growth and metastasis dissemination. These hallmarks constitute an organizing principle 
that provides a logical framework for understanding the remarkable diversity of 
neoplastic diseases. In 2000, Weinberg and Hanahan proposed six cancer hallmarks [2]: 
(1) cancer cells self-stimulate their own growth; (2) they resist inhibitory signals that 
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might prevent their growth; (3) they resist their own programmed cell death; (4) they 
stimulate the growth of blood vessels to supply nutrients to tumors; (5) they can multiply 
forever; and (6) they invade local tissue and spread to distant organs. These are the core 
common traits that govern the transformation of normal cells to cancer (malignant or 
tumor) cells. In 2011, Weinberg and Hanahan updated the cancer hallmarks by adding 4 
more [3]: (7) abnormal metabolic pathways; (8) evading the immune system (escaping 
from immunosurveillance); (9) chromosome abnormalities and unstable DNA (genome 
instability); and (10) inflammation.  
2.1 Genome duplication is an emerging cancer hallmark  
Cancer hallmarks are evolving as we understand more about cancer. For example, from 
genomic point of view, the most striking characteristic of cancer genomes is extensive 
aneuploidy. Cancer genomes carry extremely high frequency of somatic copy number 
alterations, most of which are large-scale at chromosomal level. For example, several 
chromosomal arms can be amplified or deleted. It has been proposed that genome 
duplication could play a critical role for generating cancer aneuploidies and most likely 
be a rate-limiting step for tumor development [4, 5]. This assumption is based on the 
observations that genome duplication occurs only one time and routinely at the last round 
of gene amplification/deletion events during the transformation from normal to cancer 
cells [4, 5]. Aneuploidy is extensive in cancer [6]. We and others have shown that that a 
large fraction (~50%) of solid tumors have undergone genome duplication (Milanese et 
al. unpublished data; [7]. Therefore, we regard genome duplication as an emerging cancer 
hallmark trait which not only drives cancer aneuploidies but also a rate-limiting driving 
force during tumor formation. Genome duplication enables subtle changes in the activity 
of many different genes simultaneously and could facilitate the activation of several 
hallmark networks in one shot [4, 5]. In particular, the capabilities of 
interactions/regulations between hallmark networks could easily be acquired through 
genome duplication. Therefore, activation of genome duplication network could represent 
a "perfect storm" of extreme changes of genes in the cancer genome so that a cell could 
acquire a set of cancer hallmark traits at one time and then transform a ‘slow-growing’ 
cancer clone into ‘fast-growing’ one and therefore speed up tumor formation.     
2.2 Mapping of cancer hallmark traits onto cancer hallmark networks 
Over the past few years it has been argued that network or a systems approach should be 
adopted for modeling of cancer genomic data so as to further understand cancer biology 
and translate the information into clinical practice [1, 8, 9]. In the article of ‘The 
Roadmap of Cancer Systems Biology’ [10], we proposed that a signaling network could 
be constructed for an individual tumor and modeling efforts could then be made ascribing 
cancer hallmark networks to that particular tumor. Substantial efforts have been made in 
this direction recently and have generated interesting results. For example, patient-
specific whole signaling pathways have been constructed using a graphical model 
(PARADIGM) based on genomic alteration data and used for predicting drug targets 
[11]. We have developed an algorithm by modeling cancer hallmark gene modules and 
successfully identified highly robust cancer biomarkers [12]. Moreover, by the modeling 
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of genomic alterations on the core cancer hallmark network – the cell survival and 
proliferation network - we are able to effectively predict (with 80% accuracy) breast 
cancer subtype-specific drug targets [13]. Theses examples are encouraging for modeling 
of tumor genomic data and complex cancer systems using a framework that consists of a 
set of hallmark networks representing underlying principles and mechanisms of 
tumorigenesis.        
The mechanisms of cancer etiology attributed to signaling pathways of some cancer 
hallmarks are closely intertwined. Therefore, the hallmarks whose underlying signaling 
pathways are highly intertwined can be collected into one hallmark network. For 
example, the signaling processes of Hallmarks 1, 2 and 3 are highly interactive, which 
one can define as a cancer cell survival and proliferation network (for simplicity, the 
survival network). This survival network collects the interactions and signaling processes 
of the above three hallmarks. Using this principle, we mapped cancer hallmark networks 
onto hallmark traits. Finally, we represent the complexity of cancer using only ten 
hallmark networks (Box 1).  
A cancer cell needs to acquire functional capabilities that allow it to survive, proliferate, 
disseminate and colonize (i.e., tumor metastasis) in distant organs. These functions are 
acquired in different tumor types via activating distinct hallmark networks and at various 
times during the course of multistep tumorigenesis. Among the networks, three of them 
are core networks and critical for these multistep processes. The mutation network, which 
represents Hallmark 9 (i.e., genome instability), not only is the master driver for 
tumorigenesis but also orchestrate hallmark capabilities. Acquisition of other hallmark 
traits mainly depends on the activation of the mutation network. The survival network 
represents the fundamental activities (i.e., survival and proliferation) of a cancer cell, 
while EMT network representing Hallmark 6 carries out the initial key step of tumor 
metastases. Details for the hallmark network relationships in a context of tumor 
evolutionary dynamics have been illustrated in Fig 1a.   
2.3 Quantifying cancer hallmark traits and networks to link mutant genotype to 
regulatory, molecular and cellular phenotypes of cancer cells  
Although cancer hallmark concepts have been introduced over 10 years, they are largely 
described in text. Aside from traits such as cell proliferation and EMT, most of the 
hallmark traits have no quantification measures proposed. To model cancer hallmark 
traits and networks, it is necessary to quantify not only hallmark networks but also 
hallmark traits.  We could then link network measures to hallmark trait measures using 
mathematical language.        
Network measures can be quantified at two levels: operational (i.e., regulatory) and 
molecular (i.e., functional) levels. The topological structure of a molecular network can 
be seen as computer hardware, while gene/protein regulations/interactions on the network 
can be seen as software programs which run on computers. Different cancer cells/clones 
could run distinct software programs. For example, different cancer cells have different 
sets of genomic alterations, which could trigger distinct operational (regulatory) 
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programs on the network. In this context, nodes and links in the network could be 
weighted, and certain scoring functions (representing strengths of gene/protein 
regulations) could be developed to represent gene regulatory logics/strengths on 
networks. We define a ‘network operational signature’ which is represented by a 
regulatory profile in which a set of genes form a set of regulatory circuits encoding gene 
regulatory relationships and strengths. Gene expression has been regarded as a molecular 
phenotype. Similarly, gene/protein regulatory (including signaling, protein modifications, 
and other regulatory relations such as non-coding RNA regulations) logics/strengths can 
be seen as a ‘regulatory phenotype’. A same set of genomic alterations could have 
distinct regulatory logics/strengths (i.e., regulatory phenotypes) on distinct molecular 
networks, and therefore, could lead to distinct cellular phenotypes in different cells. A 
gene expression signature representing specific molecular phenotypes can be linked to 
cellular or clinical phenotypes, therefore, we propose that network operational signatures 
representing specific regulatory phenotypes can be linked to cellular or clinical 
phenotypes as well. Details of network operational signatures associated with cancer 
hallmarks are described in Section 3.1. At the molecular level, we define network 
measures using gene expression or protein phosphorylation signatures, in which both 
gene expression and phosphorylation are treated as molecular phenotypes of cells. We 
propose phosphorylation signatures as a measuring feature due to our belief that cell 
signaling networks are critical for tumorigenesis [4, 5]. A molecular signature contains a 
list of genes and their values of either gene expression or phosphorylation, while a 
network operational signature contains a set of genes encoding their regulatory 
relationships and strengths.   
Cancer hallmark traits can be quantified based on the cell biology of the hallmarks. For 
example, cell survival could be measured by the cell proliferation rate or by the 
proliferation marker Ki-67; genome instability could be measured by the mutations 
density or deletion/amplification density per Mb chromosome; cancer dissemination 
could be measured by the number of cancer cells circuited in blood (volume) and the 
primary tumor (volume) and so on. With the quantification of the networks and their 
corresponding hallmark traits, we could model their relationships using computational 
approaches. Previously, we have modeled cancer hallmarks using gene expression 
signatures (i.e., functional gene modules of cancer hallmark networks) and these 
molecular signatures effectively predicted tumor metastasis events (Li 2010). Recently, 
we also developed an algorithm to identify network operational signatures of cancer cell 
survival networks that link to cancer cell drug targets (Tibichi et al., unpublished data). Using 
this algorithm, we correctly predicted which genes are essential to cell survival by 
providing the genomic alterations of an individual cancer cell which in turn serve as drug 
targets.    
3 Principles of the cancer hallmark network framework  
Hallmark networks possess distinctive and complementary capabilities that enable tumor 
growth and metastasis, which constitute organizing principles that provide a logical 
framework for understanding the remarkable diversity of the diseases. We hypothesize 
that a collection these hallmark networks orchestrates and drives tumorigenesis, and thus 
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forms a framework for network-based modeling and predictions of cancer phenotypes 
and clonal evolutionary paths (e.g., we could predict tumor clonal evolving several-steps-
ahead). In this framework, higher-order rules between hallmark networks in the context 
of tumor evolutionary dynamics exist (Fig 1). These rules help us to prioritize the 
networks that are more suitable for the modeling of distinct stages of tumorigenesis. By 
developing this framework, we foresee cancer research as an increasingly logical science, 
in which a myriad of phenotypic complexities are manifestations of a small set of 
underlying organizing principles.  
3.1 Transformation of genomic alternations into network regulatory phenotypes 
which quantify cellular phenotypes such as hallmark traits 
From a systems biology perspective, each hallmark network has a critical transition 
threshold (i.e., tipping point) at which the system shifts abruptly from one state to another 
[4, 5]. This tipping point can be quantified by a network operational signature and 
furthermore, it can be reflected in hallmark traits. For example, a critical transition 
threshold for a survival network is marked by the significantly different states between 
normal and cancer cells. In this context, a network operational signature could 
specifically quantify the sharp transition between States 0 and 1 (for example, for the cell 
survival hallmark, 0 represents the normal cell state while 1 represents the cancer cell 
state). In Stage 1, some hallmark traits have their own measurements, such as 
proliferation rate, which is different between cancer cells. A network operational 
signature can specifically quantify the measures of hallmark traits. In this context, we 
propose that network operational signatures of a hallmark network could be identified to 
quantify both a transition between States 0 and 1 and the measure of State 1 of hallmark 
traits.     
A series of network analyses of cancer genes showed that genes for each hallmark trait 
are most likely to be enriched in subnetworks or network communities [14-20], 
suggesting that sets of genes work together to accomplish the task. It has been proposed 
that there exist recurrent positive feedback network motifs, or functional modules, during 
the sharp transitions of States 0 and 1 [4, 5]. A network operational signature could be 
enriched with regulatory relations and strengths of the genes within one or few network 
motifs/network communities. The core hypothesis is that multiple cancer-driving factors, 
such as genomic alterations, could have thousands of combinations (ways) to trigger a 
‘state transition’ of a hallmark network.  However, to trigger a state transition they must 
go beyond the critical transition threshold which can be quantified by a network 
operational signature. Similarly, there are many ways (combinations of cancer-driving 
factors) in a hallmark network could drive different measures of a hallmark trait, but only 
a limited number of network operational signatures can quantify them. Importantly, by 
developing appropriate scoring functions, we could transform the combinations of 
cancer-driving factors (i.e., genomic alterations) into network operational signatures 
which could directly quantify hallmark traits. This modeling approach quantitatively 
links genotypes (genomic alterations) to regulatory phenotypes (regulatory 
logics/strengths), to cellular phenotypes (hallmark traits) and finally to clinical 
phenotypes (a collection of hallmark traits).             
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State transitions in network modeling are often described by activation/inactivation status 
of ‘output nodes/genes’ or ‘sink’ of networks [15]. However, in many cases, it is unclear 
which genes are the output nodes for a biological process and furthermore, output nodes 
of the networks could be different between cancer cells. It is a very challenging task to 
define the output nodes for the networks of cancer cells. Therefore, network operational 
signatures provide an effective means which overcomes the problems of defining output 
nodes of a functional network.  
3.2 Cancer cell evolution is mainly driven by a self-promoting positive feedback loop 
of hallmark networks  
The evolutionary process of cancer cells is highly dynamic, however, the outcome of 
evolution and selection will finally lead to favor hyper-proliferation and fast-growing 
cancer cells. The biology of a tumor cannot be understood by simply enumerating the 
cancer hallmark traits or networks, but instead must consider the interactions/regulations 
of these hallmark networks in terms of evolutionary dynamics. Therefore, we propose 
that the major evolutionary driving force of a cancer cell comes from a self-promoting 
positive feedback loop in which mutation network and survival network are dominant 
components (Fig 1b). In this loop, mutation network is a master activator/regulator, 
which is a driving engine for genomic alterations, while survival network is the final 
regulated target. This survival network, which continually sends positive feedback (i.e., 
selecting cancer cells with more fitness) to the mutation network, drives the evolutionary 
path of cancer cells. Mutation network induces high instability of the genome leading to 
an increase in genomic alteration occurring in the cell. New genomic alterations could be 
occurred in some components (i.e., genes/proteins) of the mutation network, which in 
turn could give the network higher efficient, thereby inducing a higher level of genome 
instability. The mutation network therefore has a self-regulating function.  
Genomic alterations induced by a mutation network could occur in the components of 
other hallmark networks so that other hallmark traits could be acquired. Cancer cell 
populations are much like an ecosystem in which fast-growing cancer cells have higher 
competitive power than slow-growing ones. Fast-growing cancer cells will be selected to 
become a dominate subpopulation within a tumor and therefore a highly efficient survival 
network will be selected. We must be made aware that the networks in the self-promoting 
loop are in the same cell. If a highly efficient survival network is selected, the mutation 
network and other networks in the loop are also selected. This selection process is 
equivalent to sending a positive feedback to these networks by the survival network. 
Combined with the knowledge that the mutation network can be self-regulated, we 
propose that the loop is a self-promoting positive feedback loop, dominated by the 
networks of mutation and survival and refer to it as self-promoting loop (Fig 1b).  
The two main classes of cancer genes are oncogenes and tumor suppressor genes. In 
general, oncogenes are often mutated or amplified in positive gene circuits, whereas 
tumor suppressor genes are often mutated, deleted or methylated in negative gene circuits 
[16]. Negative-feedback gene circuits that normally operate to dampen various types of 
signaling ensure homeostatic regulation of the flux of signals coursing through the 
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intracellular circuitry [15, 21]. Defects in these circuits are capable of enhancing 
proliferate signaling [15]. Based on the model of the self-promoting positive feedback 
loop of hallmark networks, we expect that the ‘destination’ of tumor cells is to become 
hyperproliferative in nature by self-promoting their genomes to have a higher 
hypermutation rate (i.e, a highly efficient mutation network). Therefore, the outcome of 
this self-promoting process will lead more tumor suppressor genes becoming 
mutated/deleted and more oncogenes becoming mutated /amplified. This reasoning is 
supported by a recent survey that the distribution of oncogenes and tumor suppressor 
genes is correlated with copy number alterations (i.e., amplifications and deletions) of 
chromosome arms [6].  
It is clear that the self-promoting loop mainly drives cancer cell evolution. However, 
intercellular systems could shape the path of cancer evolution. Stroma-network (e.g., 
inflammation and tumor stromal immune systems) could send signals to the networks of 
the self-promoting loop, and furthermore, tumor host immune system forms selection 
forces for cancer cells. These hallmark systems also play an important role in shaping 
cancer evolutionary path to drive tumorigenesis (Fig 1a).  
3.3 A genome duplication network activated feedforward loop is a rate-limiting step 
for tumor formation  
Genome duplication appears to be a rate-limiting step for tumor formation in many 
epithelial-origin tumor samples [4, 5]. A sharp transition between a slow-growing clone 
to a fast-growing clone could be governed by a genome duplication event yet thus far, it 
is unclear how genome duplication is triggered. Interactions between the mutation 
network of a cancer cell and its host systems such as tumor stroma-network may activate 
genome duplication network thereby trigger a genome duplication event in that cancer 
cell. This event often drives a large number of amplifications and deletions to occur 
simultaneously and in turn other hallmark networks, such as survival network, could 
quickly reach high efficiency. Therefore, the selection process after a genome duplication 
event is governed by a feedforward loop (Fig 1c) in which a genome duplication network 
is the master regulator, the dedifferentiation network, angiogenesis-inducing network and 
immune-escaping network are the secondary regulators, and survival network as the 
regulated target. If this feedforward loop is more efficient than the step-wise self-
promoting positive feedback loop, the number of amplified and deleted genes in tumors 
which experienced genome duplication could be significantly smaller than that of the 
tumors which had not experienced genome duplication. Indeed, we found that this is true 
in our analysis of a few hundreds of tumor genomes (Milanese et al. unpublished 
materials).   
3.4 Cancer cell motility initiating metastasis is a byproduct of the cancer hallmark 
self-promoting loop activity 
Tumor recurrence and metastasis are the leading cause of cancer mortality. Therapies for 
recurrent disease may fail, at least in part, because the genomic alterations driving the 
growth of recurrences are distinct from those in the initial tumor. Therefore, 
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understanding how metastasis occurs is critical. The first step of metastasis is a cancer 
cell that acquires motility governed by an epithelial-mesenchymal transition (EMT) 
network.  
As the activity of mutation network gets higher, more genomic altercations will occur in 
the genome. If certain genomic altercations hit EMT network components, a transition 
between States 0 and 1 could be triggered (i.e., 0 represents a cancer cell without motility 
capability, while 1 represents a cancer cell acquired motility capability). Once a cancer 
cell acquires the EMT trait, it starts to move out of the tumor, then circulates in the host 
systems and finally colonizes in distant organs. In this context, cancer cell motility is not 
a trait which has been selected for, but it is mainly driven by the mutation network and 
the self-promoting loop. If this is true, we expect that EMT-driven cell motility could be 
acquired by cancer cells at any time during its evolution, including the slow-growing 
stage (i.e., before primary tumor formation, or from primary tumors). However, generally 
if EMT occurs in fast-growing cells, these cells could have higher chance to undergo 
metastasis. Traditionally it is believed that metastasis occurs late in tumor formation (i.e., 
dissemination of tumor cells in late stage of tumor progression). However, a number of 
recent studies indicate that early dissemination of tumor cells occur before tumor 
formation [3].  
3.5 Mutations and other genomic alterations have specific patterns and tissue-
specificity  
For years it has been known that mutational signatures exist in cancer.  For example, both 
UV light and tobacco-smoking produce very specific signatures in a person's genome. It 
is assumed that each mutational process leaves a particular pattern of mutations, an 
imprint or signature, in the genomes of cancers it causes. Using an algorithm previously 
developed for searching mutational patterns [22], investigators  analyzed more than 7,000 
tumor genomes representing 30 most common cancer types and found sets of mutational 
signatures in tumors [23]. They found that each tumor type contains mutational 
signatures derived from at least 2 different and distinct factors such as aging, smoking, 
UV and so on. This means that we can now study those patterns that drive cancer and 
furthermore, it suggests that cancer development, progression and metastases can be 
predicted.   
 
If agent-derived mutational signatures are evenly distributed across all tissues, it is 
difficult to explain why only some agents induce certain types of tumors. With the 
assumption that a mutational signature could occur in distinct tissues and tumor types, we 
carefully checked the results obtained from a recent survey of mutational signatures 
among 30 tumor types [23] and found our hypothesis to be valid. An agent-derived 
mutational signature can indeed be tissue-dependent. For example, BRCA1/2-mutation-
derived mutational signatures dominantly occur in the tumors of breast, ovary and 
pancreas [23]. Aging-derived mutational signatures can be both age- and tissue-specific-
dependent. For example, aging-derived Siganture1A predominantly occurs in AML and 
other 6 tumor types [23]. In addition, an agent could induce two or more different 
mutational signature profiles which could occur in distinct tissues. For example, 
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APOBEC is able to induce at least two different mutational signatures: one occurs in 16 
tumor types while the other occurs in 2 other tumor types [23]. Furthermore, a recent 
study showed that tissue-specific mtDNA mutation signatures are common, even in 
normal tissues, and also showed that most of these signatures are aging-driven [24]. This 
study underscores that human DNA changes or mutates in patterns rather than randomly.   
 
These mutational signatures will be extremely useful for modeling genome sequencing 
data using the hallmark network-based framework. Therefore, it is critical to survey more 
genomes with different ages and from different tissues, to create a compendium of 
mutational signatures triggered by the aging process. In addition, a similar effort should 
be taken in collecting mutational signatures derived from cancer-inducing factors 
(including chemotherapy drugs and therapy-based radiations) in different tissues and 
cancer types.  
 
4 Strategies for constructing predictive models using a hallmark network 
framework    
 
Tumor progression can be portrayed as a succession of clonal expansions, each of which 
is triggered by the interactions of a set of hallmark networks [4, 5]. Starting from a 
normal cell to a cancer clone, new mutations during clonal expansion will build on the 
existing mutation profiles of previous clones. Therefore, a hallmark network can be 
updated and examined to check if the newly added mutations could work together with 
the ‘pre-existing mutations’ of the network to trigger a state transition or modulate the 
measures of a hallmark trait. Mutational patterns can be treated as key factors in the 
modeling experiments. For example, age-associated mutational patterns are major driving 
force for tumorigenesis. Different age groups have distinct mutational patterns, but they 
do not exist across all the tissue types. If we know the mutational patterns driven by 
aging or other factors, we could simulate the mutations of the proteins (or the regulatory 
or post-modification elements of the proteins such as transcription factor binding sites 
and phosphorylation motifs), which contain sequences matching that mutational pattern 
(Fig 2a).  From there we could predict which proteins on a network could become 
mutated and whether this mutation works together with the ‘pre-existing mutations’ of 
the network to trigger the activation of a hallmark network by comparing with network 
operational signatures (Fig 2a). Network operational signatures could be identified from 
the gene regulatory profiles, which are generated from the network of normal and tumor 
samples. By doing so, cancer clonal evolution becomes largely predictable. The 
predictability of tumor clonal evolution means that we could foresee clonal evolutionary 
paths and then design cancer therapies to effectively conduct individualized cancer 
treatment.  
 
More than 10,000 tumor genomes have been sequenced and this effort is still ongoing. It 
is expected that more tumor genomes and their matched gremlin genomes will be 
sequenced in the near future. Using these data, we can obtain network operational 
signatures for quantifying state transitions and measures for hallmark traits. Using these 
signatures and the hallmark network framework we can construct models that predict 
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how the tumor will evolve and the risk potentials for healthy people who have certain 
germline mutations which could induce cancers.  
 
4.1 Predictive models for a cancer patient  
 
When a patient has a primary tumor only (i.e., metastasis has not been detected yet), it 
would be interesting to predict: 1) the possibility of tumor recurrence and metastases; 2) 
which drugs could be applied; and 3) the potential consequences after applying a specific 
drug. This information could aid in the design of therapies of appropriate first line of 
treatment and avoiding drug resistance derived from a specific drug treatment. 
 
There are at least three key steps in the transformation of a normal cell to a metastatic cell 
(i.e., from a normal to a cancer cell; from a cancer cell to a circulating cell; and then to a 
metastatic cell which has been colonized in another organ). In this process, survival 
networks could be undergoing at least three key rounds of rewiring so that the drug 
targets for these three clinical phenotypes could be different. It would be useful to predict 
drug targets not only for the primary tumor, but also for the circulating cells so that 
circulating cancer cells could also get treated. As mentioned above, modeling of survival 
networks could predict drug targets for individual cancer cells. The survival signaling 
network can be constructed based on genome-wide RNAi knockdown data. Previously, 
we constructed breast cancer subtype-specific survival networks which were used for 
predicting subtype-specific drug targets with 80% accuracy (Zaman 2013). Recently, we 
developed network operational signatures of survival networks that enabled prediction of 
drug targets specifically for a single cancer cell/clone with 90% accuracy (Tibiche et al., 
manuscript in preparation). This tool allows predicting drug targets for each clone within 
a tumor based on their genomic alteration profiles. The genomic alternation profiles of 
primary tumor clones and the circulating cancer cells can be used for predicting their 
drug targets. 
 
Currently, patients are often treated with generic cancer chemotherapeutic drugs which 
are often toxic and may also induce new mutations to tumor cells. To predict potential 
drug resistance, we could apply a specific drug to determine the mutational patterns 
driven by that drug on survival networks. For example, a drug can be applied to different 
cancer cell lines, followed by genome sequencing to identify mutational patterns derived 
from that specific drug treatment. If the mutational pattern driven by a specific drug that 
is to be applied to a patient is known, we could simulate the mutations of the proteins 
(whose sequences match the mutational pattern, of the current survival networks of the 
tumor clones) to predict the probability of drug resistance and help in making clinical 
decisions whether a drug should be applied to that patient. It should be noted that for that 
same drug, the probability of drug resistance varies between different patients (i.e., their 
survival networks have distinct pre-existing genomic alteration profiles).   
 
To predict metastasis of a primary tumor, it is possible to simulate protein mutations of 
the EMT network based on mutational patterns learned from that tumor combined with 
aging-associated mutational patterns. The same method could apply to the mutation 
network and the immune-escaping network for the circulation and colonization processes 
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of a cancer cell. In addition, host immune repertoire deep sequencing data could be 
integrated to examine the probability of tumor recurrence and metastasis.  
 
The collection of these predictions could help in understanding of the mechanisms by 
which invading cells give rise to recurrent tumors and the effect of adjuvant therapeutics 
have on their evolution which will facilitate the development of new strategies to delay or 
prevent recurrence and malignant tumor progression. 
 
4.2 Predictive models for cancer risk for healthy individuals  
 
At the moment, cancer predisposition genes in germline cells are the major genetic 
factors to be used for evaluating cancer risks for a healthy person. To date, ~114 cancer 
predisposition genes have been identified [25]. The assumption is that if a cancer is 
detected early, treatment and survival will be improved. Preventative measures can be 
taken, such as the surgical removal of the at-risk tissue, however, it is preferable to 
conduct chemoprevention for persons at-risk. For example, taking an aspirin daily 
significantly reduced the risk of colorectal cancer for men who have mismatch repair 
gene mutation in germline cells [26]. However, it is unwise to use a single cancer 
predisposition gene to judge all cancer risks and we propose using the cancer hallmark 
framework (Fig 2b) could more effectively evaluate cancer risks based on a person’s 
genomic profiles derived from blood cells. 
 
We will consider the germline and aging mutational profiles, as well as potential 
environmental factors for inducing cancers in the framework. The self-promoting 
feedback loop (Fig 1b) containing both the mutation network and survival network could 
provide a window of opportunity for mitigating or preventing cancer. As shown in Fig 
2b, hallmark networks will be first mapped using the mutations from the germline 
genomic profile, followed by other potential mutations based on the mutational patterns 
derived from aging and other potential cancer inducing agents (e.g., if a person is a heavy 
smoker, mutational patterns triggered by smoking will be projected). Network operational 
signatures can be used for predicting if and when the person could develop cancer. In this 
model, aging is considered as a major driving force for tumorigenesis: for example, 
nearly half of cancer patients are diagnosed after 65 years of age. Moreover, genome-
wide age-related DNA methylation changes in blood and other tissues related to histone 
modification, expression and cancer, revealed the existence of age-specific DNA 
methylation genes [27], which suggests that age-specific mutation patterns exists. 
Furthermore, age-associated mutational patterns are tissue-specific. Given this strategy, 
the incidence and timing of malignant tumor progression can potentially be predictable. 
Because this prediction is based on hallmark networks in which gene regulatory profiles 
can be generated by mutations, it is possible to predict potential drug targets using the 
regulatory profiles. Therefore, it is possible to apply drugs for personalized cancer 
prevention.   
 
5 Challenges   
Our framework consists of a set of cancer hallmark networks. However, at the moment 
only a few hallmark networks are relatively rich in information, such as cell survival, 
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mutation (i.e., genome instability) and EMT networks. Comprehensive information for 
other hallmark networks is still not available:  a reasonably complete stroma-network is 
still not available as the great majority of signaling molecules and pathways remain to be 
identified. This reality poses challenges in using this framework to explore the 
interactions between stoma and cancer cells in orchestrating malignant progression.  
 
Mutational patterns are critical factors in constructing predictive models, however, 
mutational patterns derived from aging, chemo and popular germline mutations have 
been not extensively catalogued. It is therefore important to gather a comprehensive 
compendium of mutational patterns for the understanding of cancer development and aid 
in constructing predictive models. Finally, it is essential to develop optimized network 
scoring functions for network modeling and network operational signatures for hallmark 
networks.    
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Fig 1. Cancer hallmark networks and their relationships in the context of tumor 
clonal evolutionary dynamics. Fig 1a represents the regulatory relationships of cancer 
hallmark networks. Fig 1b represents a self-promoting positive feedback loop which is 
the dominantly driving force for cancer clonal evolution. In this loop, mutation network 
is a master activator/regulator, which is a driving engine for genomic alterations, while 
survival network is the final regulated target. This survival network, which continually 
sends positive feedback to the mutation network, drives the evolutionary path of cancer 
cells. Fig 1c represents a feedforward loop in which a genome duplication network is the 
master regulator, the dedifferentiation network, angiogenesis-inducing network and 
immune-escaping network are the secondary regulators, and survival network as the 
regulated target. The hallmarks represented by each network have been explained in Box 
1. Networks in blue, red and green represent immune-escaping network, angiogenesis-
inducing network, and dedifferentiation network, respectively. Line with arrows 
represents an inducing (positive) or interaction relationship, while open circle with 
double arrows represents self-regulation.    
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Fig 2. Constructing predictive network models using the cancer hallmark network 
framework. Based on the relationships and functions of the hallmark networks, distinct 
networks could be modeled, for example, for predicting drug targets, survival network 
could be modeled; for predicting cancer risk, mutation network and survival network 
could be modeled; for predicting cancer recurrence, EMT network and stroma-network 
could be modeled. For each predictive model, network operational signatures, mutational 
patterns and so on will be used. New mutations based on mutational patterns of cancer-
inducing agents could be projected onto the networks. Gene regulatory profiles (i.e., 
representing regulatory phonotype) could be generated based on the new and pre-existing 
mutations on the networks. The profiles will be compared with network operational 
signatures to predict the outcomes of the newly added mutations. Here mutation has a 
broad definition: it could be any genetic and epigenetic changes. A network operational 
signature is a specifically regulatory profile in which a set of genes encodes their 
regulatory logics and strengths. Fig 2a, predictive network models for cancer patients. 
These models could predict drug targets of tumor clones, prognosis, and drug resistance. 
The figure shows a case that within a tumor three clones can be identified. Each clone 
will be modeled independently. The final result of the tumor will be dependent on the 
outcomes of the three clones. Fig 2b, cancer risk predictive network models for healthy 
individuals. Exome-sequencing data of germline cells will be incorporated into 
mutational patterns derived from aging, cancer predisposition genes or other cancer-
inducing agents. These data will be modeled on hallmark networks to predict whether and 
when a tumor could occur for a healthy individual.            
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Box 1: Mapping cancer hallmark networks to hallmark traits 
Survival network represents underlying molecular mechanisms for the most fundamental trait 
of cancer cells involves their ability to sustain chronic proliferation, resist to cell death, and 
resist inhibitory signals that might prevent their growth. It represents a collection of three 
hallmark traits whose underlying biological processes and signaling pathways are highly 
intertwined and cross-talked.  
Mutating network represents regulatory mechanisms that trigger high level of genome 
instability and induce high mutation rate of the genome.  
Dedifferentiation network represents molecular mechanisms of the capability of unlimited 
replicative potential of tumors.  
Angiogenesis-inducing network represents underlying molecular mechanisms for 
angiogenesis which provides tumors for accessing nutrients and oxygen and evacuating 
metabolic wastes. It represents stimulating the growth of blood vessels to supply nutrients to 
tumors.  
 
Immune-escaping network represents a mechanism for escaping immune surveillance from 
host by cancer cells.  
EMT (epithelial-mesenchymal transition) network represents regulatory machinery that 
allows cancer cells requiring cell motility ability. Invasion and metastasis has multisteps: 
cancer cells acquire motility capability, disseminate and circulate in host, and finally colonize 
in distant organs. EMT network captures the first step of this process. Other steps involved in 
extensive interactions between cancer cells and tumor microenvironment, which is represented 
by a stroma-network.     
Genome duplication network represents a molecular mechanism of triggering genome 
duplication during cancer clonal evolution. This mechanism has been proposed as a rate-
limiting driving force during tumor formation. 
 
Metabolic network represents a molecular mechanism of reprogramming energy metabolism 
which leads to aerobic glycolysis. 
Stroma-network represents complex interactions between stroma and tumor cells. These 
interactions could have multiple functions such as tumor-promoting inflammation, immune 
responses that could eradicate tumors, or other supporting functions for tumor growth.  
